Biocartis announces change in Board composition
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Mr. Roald Borré has resigned as Director of the Company, and that upon the recommendation of the Company’s Remuneration and Nomination Committee, the Board of Directors has appointed Mr. Bryan Dechairo as new independent Board member and member of the Audit Committee of the Company.
Mr. Bryan Dechairo is the chief executive officer of Sherlock Biosciences, and also serves on its Board of Directors. He has more than 25 years of experience developing and commercializing revenue generating clinical innovations that improve patient lives. Prior to joining Sherlock Biosciences, Mr. Dechairo served as executive vice president of clinical development at Myriad Genetics, where he oversaw the development portfolio, delivering business-critical evidentiary data for value-based reimbursement and market acceptance of commercial and novel diagnostic products across six business units globally. Before joining Myriad Genetics, he was chief medical officer, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. During his extensive career, Mr. Dechairo held roles of increasing responsibility at Medco, Pfizer, Oxagen, Sequana and Roche, where he established a proven track record of funding and scaling businesses from venture backed start-ups to profitable fortune 50 public companies. He also authored more than 50 academic and research-based publications, and earned a Ph.D. in Common Complex Human Genetics from the Institute of Child Health at University College London and a B.A. in Integrative Biology from the University of California, Berkeley.
Herman Verrelst, Chief Executive Officer of Biocartis, said: “We are very pleased that Bryan is joining our Board, and look forward to benefitting from his extensive experience. His appointment takes place in the framework of our continuous strive for a diverse Board of Directors which has all required skills and experience to support Biocartis as a commercial-stage innovative molecular diagnostics company that operates internationally. We are sure that Biocartis will benefit tremendously from his skills and deep knowledge of the US market. Of course, we wish to thank Roald for his enormous contribution to the Company over the past eight years.”
Following this change in Board composition, the Board now consists of five independent directors out of a total of six directors. Mr. Dechairo’s appointment will be submitted to the confirmation by the Company’s annual shareholders’ meeting which will be held on 12 May 2023.